LivaNova Set for Major Growth as Medicare Ups Reimbursement for VNS Therapy Procedures in 2026
Significant Medicare Boost: 48% Increase in Outpatient Payments for VNS Therapy Procedures
LivaNova PLC, a global leader in medical technology, is on the verge of a meaningful shift following a landmark announcement by the U.S. Centers for Medicare & Medicaid Services (CMS). Starting January 1, 2026, LivaNova's VNS Therapy™ procedures for drug-resistant epilepsy will be classified under New Technology Ambulatory Payment Classification (APC) 1580 for new patient implants and Level 5 APC for end-of-service (EOS) procedures. This move means hospital outpatient payments will increase by roughly 48% for new patient implants and 47% for EOS procedures compared to 2025 rates—a boost set to reshape hospital economics and, potentially, patient care access.
| Procedure Type | APC Level (2026) | % Payment Increase vs. 2025 |
|---|---|---|
| New Patient Implant (NPI) | New Tech APC 1580 | 48% |
| End-of-Service (EOS) | Level 5 APC | 47% |
Hospital Economics Improve—Barriers to Patient Access Lowered
This payment change targets a key barrier: previous Medicare outpatient reimbursement often did not fully cover hospital costs, stalling wider adoption of VNS Therapy. The improved financial landscape could allow more hospitals to offer the therapy to Medicare patients, directly addressing the needs of the significantly underserved drug-resistant epilepsy (DRE) community. With these enhanced economics, the pathway for hospitals and physicians to adopt the therapy for eligible patients becomes much more sustainable.
Strong Clinical Results Underscore Therapy’s Promise
Alongside the reimbursement boost, LivaNova highlights new real-world clinical data that underlines VNS Therapy's effectiveness for people with DRE. The CORE-VNS study—the largest real-world neuromodulation study for epilepsy—shows:
- 80% median seizure reduction at 36 months for focal onset motor seizures with impaired awareness
- 95% median seizure reduction for focal to bilateral tonic-clonic seizures
The procedure remains low-risk and minimally invasive, with most patients reporting only mild side effects such as hoarseness and sore throat. According to recent surveys, 94% of VNS Therapy patients and caregivers wished they had found this therapy earlier, reflecting strong satisfaction.
Broader Market Implications—Will Patient Access Expand Further?
This Medicare reimbursement update is more than a technical billing shift. By significantly reducing economic friction, LivaNova stands to accelerate adoption of VNS Therapy in hospitals nationwide. Given that drug-resistant epilepsy affects approximately one in three people with epilepsy and current penetration remains low, investors and stakeholders may want to monitor whether hospital adoption and patient access accelerate in coming years.
Key Takeaways for Stakeholders
- Effective January 1, 2026, VNS Therapy will receive a near 50% boost in Medicare outpatient payments, removing a critical hospital adoption barrier.
- Strong clinical outcomes reinforce the therapy’s relevance, supporting the potential for broader usage in the U.S. DRE patient population.
- The upcoming reimbursement change sets up LivaNova for potential revenue and patient access gains, subject to actual hospital uptake and ongoing payer policy.
With CMS’s decision now in place, investors, patients, and the broader neuromodulation market have reason to watch 2026 as a pivotal year for both LivaNova and epilepsy care expansion.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI